Joan Mary Quigley

Joan Mary Quigley

Auto-generated profile, based on publicly available information

Joan Mary Quigley

Health Research Board

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2018 in Journal of Evaluation in Clinical Practice
Verified
Journal Article
Closed access
PDF file
JQJoan M. Quigley
Joan M. Quigley
JTJuliette C. Thompson
Juliette C. Thompson
NHNicholas J. Halfpenny
Nicholas J. Halfpenny
DSDavid Scott
David Scott

13 October 2018 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
NMNeerav Monga
Neerav Monga
LNLoretta Nastoupil
Loretta Nastoupil
JGJamie Garside
Jamie Garside
JQJoan Quigley
Joan Quigley
MHMoira Hudson
Moira Hudson
CTCatherine Thieblemont
Catherine Thieblemont

22 November 2021 in Tobacco Prevention & Cessation
Verified
Journal Article
Open access
JQJoan M. Quigley
Joan M. Quigley
CWCathal Walsh
Cathal Walsh
CLCaitriona Lee
Caitriona Lee
JLJean Long
Jean Long
HKHelen Kennelly
Helen Kennelly
PKPaul Kavanagh
Paul Kavanagh
Introduction: This systematic review of randomized controlled trials (RCTs) evaluated the efficacy and safety of electronic cigarettes (e-cigarettes, ENDS) in helping people who smoke to achieve abstinence compared with electronic non-nicotine delivery systems (ENNDS, no nicotine) or any...

29 September 2016 in BMJ Evidence-Based Medicine
Verified
Journal Article
Closed access
PDF file
NHNicholas James Anthony Halfpenny
Nicholas James Anthony Halfpenny
JQJoan Mary Quigley
Joan Mary Quigley
JTJuliette Catherine Thompson
Juliette Catherine Thompson
DSDavid Scott
David Scott
Peer-reviewed publications and conference proceedings are the mainstay of data sources for systematic reviews and network meta-analyses (NMA), but access to informative unpublished data is now becoming commonplace. To explore the usefulness of three types of ‘grey’ literature-clinical trials registries, clinical study reports and data from regulatory authorities-we conducted four case studies. The reporting of outcome data in peer-reviewed publications, the clinical trials registries and the clinical study reports for two clinical trials—one in melanoma, one in juvenile idiopathic arthritis (JIA)—was examined. In addition, we assessed the value of including unpublished data from the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) in evidence syntheses of hepatitis C virus (HCV) and chronic obstructive pulmonary disease (COPD), respectively. For the clinical trials in melanoma and JIA, we identified outcome parameters on ClinicalTrials.gov additional to those reported in the peer-reviewed publications: subgroup data and additional efficacy end points/extended follow-up, respectively. The clinical study report also provided results for several subgroups unavailable elsewhere. For HCV and COPD, additional outcome data were obtained from the EMA European Public Assessment Report (EPAR) and the FDA, respectively, including data on subgroups and mortality. We conclude that data from these grey literature sources have the potential to influence results of systematic reviews and NMAs, and may thus have implications for healthcare decisions. However, it is important to consider carefully the availability, reliability and consequent usability of these data sources in systematic reviews and NMAs.

24 February 2016 in BMJ Evidence-Based Medicine
Verified
Journal Article
Closed access
PDF file
JTJuliette Catherine Thompson
Juliette Catherine Thompson
JQJoan Mary Quigley
Joan Mary Quigley
NHNicholas James Anthony Halfpenny
Nicholas James Anthony Halfpenny
DSDavid Scott
David Scott
NHNeil Stephen Hawkins
Neil Stephen Hawkins

3 March 2015 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
JQJoan M. Quigley
Joan M. Quigley
PBPeter A. Bryden
Peter A. Bryden
DSDavid Scott
David Scott
HKHiroyo Kuwabara
Hiroyo Kuwabara
KCKarin Cerri
Karin Cerri